Bausch + Lomb Names Thomas J. Appio Interim CEO, Raises 2026 Guidance Expectations
Bausch + Lomb Appoints Thomas J. Appio as Interim CEO as Brent Saunders Departs Bausch + Lomb Corporation, a leading global eye health company, and its parent company, Bausch Health…
BIOMAG™-LL Study Completes Enrollment for Freesolve™ Magnesium Scaffold
BIOMAG™-LL Study Completes Enrollment for Longer Freesolve™ Magnesium Scaffolds Teleflex Incorporated (NYSE: TFX), a global provider of medical technologies, has announced the successful completion of patient enrollment in the BIOMAG™-LL…
Final MINT Study Results Support Real-World Effectiveness of Poteligeo® in MF and Sézary Syndrome
Final MINT Study Results Highlight Real-World Benefits of Mogamulizumab in Mycosis Fungoides and Sézary Syndrome Kyowa Kirin International plc, a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE: 4151),…
bioAffinity Technologies Closes $4 Million Registered Direct Offering and Concurrent Private Placement
bioAffinity Technologies Closes $4 Million Registered Direct Offering to Support CyPath® Lung Sales and Corporate Operations bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company developing noninvasive healthcare solutions for…
Corcym Reports Positive Perceval Plus Heart Valve Data With Up to 7-Year Follow-Up
Corcym Reports Positive Seven-Year Mid-Term Data for Perceval Plus Sutureless Aortic Valve in MANTRA Clinical Study Corcym, a global medical device company focused on cardiac surgery, has announced positive mid-term…
Affinia Therapeutics’ AFTX-201 and UPBEAT™ Trial Featured at HFSA 2026
Affinia Therapeutics to Present AFTX-201 Preclinical Data and UPBEAT Trial Progress in BAG3-Associated Dilated Cardiomyopathy at HFSA 2026 Affinia Therapeutics, a clinical-stage gene therapy company developing potentially first-in-class and best-in-class…
Secretome Therapeutics to Present Phase 1 STM-01 Data in HFpEF at HFSA Meeting
Secretome Therapeutics to Present Phase 1 Clinical Data for STM-01 in Heart Failure With Preserved Ejection Fraction Secretome Therapeutics, a clinical-stage biotechnology company developing innovative therapies derived from neonatal cardiac…
Glaukos Reports Positive Phase 4 Results for iDose® TR Combined with Cataract Surgery
Glaukos Reports Positive Phase 4 Results for iDose TR Combined With Cataract Surgery in Glaucoma Patients Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company developing innovative treatments…
Seaport Therapeutics Presents New GlyphAgo™ Phase 1 Pharmacokinetic Data at ECNP Congress
Seaport Therapeutics Presents Phase 1 Clinical Data Showing Improved Bioavailability and Reduced Pharmacokinetic Variability for GlyphAgo Seaport Therapeutics, Inc. (Nasdaq: SPTX), a clinical-stage therapeutics company focused on developing innovative medicines…
Ascensia Partners with Sava to Advance Innovative Microsensor Technology
Ascensia Diabetes Care Partners with Sava Technologies to Advance Wearable Microsensor Technology for Glucose Monitoring Ascensia Diabetes Care, a global diabetes care company and subsidiary of PHC Holdings Corporation (Tokyo…
FDA Approves Genentech’s Tecentriq Combination for Stage III Colon Cancer Adjuvant Treatment
Genentech’s Tecentriq Receives FDA Approval for Adjuvant Treatment of Stage III dMMR Colon Cancer Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced that the U.S.…
INBRAIN and MINIGRAPH Develop Robotic Implantation for Graphene Brain-Computer Interfaces
INBRAIN Neuroelectronics Completes MINIGRAPH Project, Advancing Graphene-Based Brain-Computer Interfaces and Robotic Neural Implantation INBRAIN Neuroelectronics, a clinical-stage neurotechnology company developing graphene-based brain-computer interface (BCI) therapeutics, has announced the successful completion…